Harmonising drug-target binding data analytics on a single platform
Supported by:
13 November 2018
ABOUT THIS WEBINAR
In early stage medicines research, measuring in vitro drug-target interaction characteristics is a critical path activity in selecting therapeutic candidates for progression into pre-clinical models. Technologies and instrumentation used in this space are numerous. Bespoke instrument-specific data analysis software make the data handling and result-publishing workflow disjointed. It requires too many manual data handling steps leading to inefficiency and elevated risks to data integrity. In research scenarios such as this, efficient handling, processing and publishing of high volumes of experimental data is critical for objective decision making and selecting optimal therapeutic candidates.
This webinar outlined the fundamentals of a design process where an experimental analytics data workflow is being integrated into a more seamlessly interactive digital platform.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Analysis, Assays, Big Data, Drug Discovery, Drug Discovery Processes, Hit-to-Lead, Imaging, In Vitro, In Vivo, Informatics, Lab Automation, Molecular Targets, Research & Development, Screening, Sequencing, Translational Science
Related organisations
GSK (GlaxoSmithKline), PerkinElmer
